Advertisement

Search Results

Advertisement



Your search for Roy S. Herbst, MD, PhD matches 59 pages

Showing 51 - 59


issues in oncology
health-care policy

ASCO and AACR Call for Regulation of E-Cigarettes and Other Electronic Nicotine Delivery Systems

The American Association for Cancer Research (AACR) and ASCO have outlined steps in a joint statement to guide policymakers as they work to minimize the potential negative consequences of electronic cigarettes (e-cigarettes) and other electronic nicotine delivery systems without undermining their...

lung cancer

Top 10 Lessons Learned So Far About Treating Lung Cancer With Immunotherapy

Immunotherapy agents “really work” in treating lung cancer, but they have unique toxicities, are challenging to combine with other therapies, and questions remain about dose and duration, Roy S. Herbst, MD, PhD, stated at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. “There are ...

lung cancer

EGFR L858R Mutation in Blood Sample May Serve as Surrogate for Biopsy in Determining EGFR-Mutation Status

Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown that the EGFR L858R...

Expert Point of View: Roy S. Herbst, MD, PhD

Results of CheckMate 057 represent excellent progress, but they are not truly ‘checkmate,’” said Roy S. Herbst, MD, PhD, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, Associate Director for Translational Research at Yale Cancer Center in New Haven, Connecticut....

Yale Cancer Center Receives $11 Million SPORE Grant for Lung Cancer Research

The National Cancer Institute (NCI) recently awarded Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven a Specialized Program of Research Excellence, or SPORE, grant worth $11 million. The Yale SPORE will launch a new research program in non–small cell lung cancer. The new research...

Nationally Regarded Oncology Nurse Practitioner, Mary Pazdur, RN, MSN, Remembered by Friends and Colleagues

Oncology nurse practitioner Mary Pazdur, RN, MSN, spent her professional life bettering the clinical care and outcomes of cancer patients, culminating in her career at the National Cancer Institute (NCI), in the Laboratory of Tumor Immunology and Biology, working with patients on cancer vaccine...

lung cancer
integrative oncology

WCLC: Cetuximab May Improve Survival in Some Patients With EGFR-Positive Squamous NSCLC

Analysis of a large phase III trial (S0819) suggested that adding the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab (Erbitux) to chemotherapy benefits survival in patients with squamous cell non–small cell lung cancer (NSCLC) with tumors positive...

issues in oncology
lung cancer

EGFR L858R Mutation in Circulating Free DNA From Blood Samples of Patients With Non–Small Cell Lung Cancer Shown to Be Negative Prognostic Marker

Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown...

ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers

A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...

Advertisement

Advertisement



Advertisement